Astrotech Corp (ASTC) - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Astrotech Corporation for the quarterly period ended December 31, 2024. Astrotech is a Delaware corporation developing and commercializing mass spectrometry (MS) technology through wholly-owned subsidiaries: 1st Detect (security/explosives detection), AgLAB (agriculture/cannabis), BreathTech (breath analysis), and Pro-Control (industrial process control). The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2023 |
|---|---|---|---|
| Revenue | $261 | $295 | $1,540 |
| Gross Profit | $155 | $164 | $715 |
| Gross Margin | 59% | 56% | 46% |
| Operating Expenses | $4,476 | $8,113 | $7,118 |
| Net Loss | $(4,009) | $(7,287) | $(5,553) |
| Net Loss Per Share (Basic/Diluted) | $(2.45) | $(4.46) | $(3.40) |
Liquidity and Balance Sheet
- Cash and Cash Equivalents: $3.2 million as of December 31, 2024, down from $10.4 million at June 30, 2024.
- Short-term Investments: $21.5 million (Available-for-sale securities).
- Total Assets: $31.0 million.
- Total Liabilities: $2.9 million.
- Working Capital: Approximately $25.5 million.
- Debt: No long-term debt reported; liabilities consist primarily of lease obligations ($142k total) and accrued expenses.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 77% year-over-year for the six-month period ($295k vs. $1.54M). Management attributes this to selling fewer TRACER 1000 devices in the current period compared to the prior year.
- Margin Expansion: Despite lower revenue, gross margin improved to 56% (from 46% prior year) due to a sales mix with higher-margin device sales and grant revenue with minimal cost of revenue.
- Increased Operating Expenses: Operating expenses rose 14% year-over-year ($8.1M vs. $7.1M). Research and Development (R&D) expenses increased by $936k (27.1%) due to increased contractor and employee spending to support mass spectrometry development.
- Cash Burn: Net cash used in operating activities increased to $6.7 million for the six months ended Dec 31, 2024, compared to $4.9 million in the prior year period.
Outlook, Risks, and Unusual Items
- Subsequent Events:
- Executive Change: Jaime Hinojosa resigned as CFO effective February 14, 2025. Ryan Polk was appointed Interim CFO.
- New Contracts: 1st Detect received a $429k purchase order from a TSA contractor (Intuitive Research) and a DHS R&D contract for the TRACER 1000.
- Lease Expansion: Entered a new lease for a 17,628 sq. ft. facility ("Metric facility") in Austin, commencing August 31, 2025, with a total obligation of approximately $3.2 million.
- Risks:
- Customer Concentration: One customer comprised all revenue for the three and six months ended December 31, 2024.
- Supply Chain: Reliance on single-source suppliers for critical components creates vulnerability to shortages and price fluctuations.
- Liquidity: The company continues to fund operations through cash reserves and investments, with a history of net losses and an accumulated deficit of $244.3 million.
- Guidance: The filing does not provide specific numerical financial guidance for future periods. Management expects the effective tax rate to remain 0% for fiscal year 2025 due to valuation allowances on deferred tax assets.
Investor Verification Checklist
- Customer Concentration: Verify the identity and stability of the single customer responsible for 100% of recent revenue.
- Cash Runway: Assess the sustainability of the current cash burn rate (~$6.7M per six months) against the $24.7M in liquid assets (cash + short-term investments).
- Revenue Recognition: Confirm the timing of revenue recognition for the new $429k purchase order and the DHS R&D contract mentioned in subsequent events.
- Lease Obligations: Review the financial impact of the new $3.2M lease commitment starting in August 2025.
- R&D Efficiency: Evaluate the progress of R&D spending ($4.4M for six months) relative to product milestones and commercialization timelines.